Lianhuan Pharmaceutical Its amlodipine besylate tablets were approved in the country
September 6, 2025
Source: drugdu
106
On September 4, Lianhuan Pharmaceutical announced that its subsidiary, Xinxiang Changle Pharmaceutical Co., Ltd., had received approval in China for its amlodipine besylate tablets. Amlodipine besylate tablets are a commonly used medication for regulating vascular pressure. In 2024, sales of amlodipine besylate tablets (2.5mg/5mg/10mg) in hospitals nationwide reached 1.216 billion yuan.
Comment: This event further enriches the product lines of the company and its subsidiaries, helping to enhance the market competitiveness of their products. However, this market is already crowded with numerous participants and fiercely competitive. The company needs to strengthen its marketing and channel development efforts to effectively increase its market share.
https://finance.eastmoney.com/a/202509053505290366.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
